International Conference on Conceptual Modeling

Nusano to Participate in Isotope and Radiopharmaceutical Conferences

Retrieved on: 
Thursday, July 20, 2023

VALENCIA, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, today announced participation in two conferences in July 2023.

Key Points: 
  • VALENCIA, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, today announced participation in two conferences in July 2023.
  • Nusano CEO Chris Lowe will present an overview of the company’s breakthrough radioisotope production platform at the 2nd Annual Targeted Radiopharmaceuticals Summit on July 26 in Boston.
  • Nusano is also presenting two abstracts in oral presentations at the 11th International Conference on Isotopes, in Saskatoon, Saskatchewan, Canada on July 26 and 27.
  • Supplying the Fight Against Cancer: Nusano’s Breakthrough Radioisotope Production Platform

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Retrieved on: 
Friday, June 9, 2023

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
  • “We’re pleased to be sharing updated LOTIS-2 results demonstrating the long‐term efficacy and safety of ZYNLONTA with the lymphoma community at EHA2023 and 17-ICML,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The median (range) time to response was 41.0 (35 to 247) days for all responders and 42.0 (36 to 247) days for patients with a CR.
  • All-grade treatment‐emergent adverse events occurring in ≥30% of all patients were increased gamma-glutamyltransferase (42%), neutropenia (40%), and thrombocytopenia (33%).

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

Retrieved on: 
Thursday, May 25, 2023

CUPERTINO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis (IPF) at the 2023 American Thoracic Society (ATS) International Conference which took place in Washington, DC, USA, May 19-24, 2023. The Company also announced acceptance of this data for publication in Medical Research Archives. The ATS poster and online publication will be available at revivapharma.com/publications.

Key Points: 
  • The Company also announced acceptance of this data for publication in Medical Research Archives.
  • “This preclinical evaluation in IPF provides proof-of-concept support for the potential of brilaroxazine to treat pulmonary fibrosis and inflammation stemming from underlying dysfunction in serotonin signaling in the lung.
  • Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter.
  • Brilaroxazine demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF.

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Retrieved on: 
Thursday, May 25, 2023

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023.
  • Presentations will include data from clinical trials evaluating the efficacy of epcoritamab in combination with standard-of-care therapies for the treatment of various types of B-cell non-Hodgkin lymphoma (NHL), including first-line, high-risk diffuse large B-cell lymphoma (DLBCL), relapsed or refractory large B-cell lymphoma (LBCL), and relapsed or refractory follicular lymphoma (FL).
  • The safety and efficacy of epcoritamab has not been established for these investigational uses.
  • Abstracts accepted for presentation at ASCO include:

ATD Recognizes Exceptional Achievements in the Talent Development Industry

Retrieved on: 
Wednesday, May 24, 2023

ALEXANDRIA, Va., May 24, 2023 /PRNewswire-PRWeb/ -- During its 2023 International Conference & Exposition in San Diego, California, the Association for Talent Development (ATD) recognized organizations and individuals for their excellence and contributions across the talent development field.

Key Points: 
  • The Association for Talent Development honored organizations and individuals for their commitment to workplace talent development practices.
  • ALEXANDRIA, Va., May 24, 2023 /PRNewswire-PRWeb/ -- During its 2023 International Conference & Exposition in San Diego, California, the Association for Talent Development (ATD) recognized organizations and individuals for their excellence and contributions across the talent development field.
  • This award recognizes innovation that has had a measurable impact on an organization or audience, is moving the talent development industry forward, is sustainable, and is replicable within or outside the talent development field.
  • LeapFrog Investments was honored with the Talent Development for Good Award, which recognizes organizations that leveraged talent development to make significant contributions to improve the lives of others, change an industry or community for the better, or powerfully serve society.

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

Retrieved on: 
Monday, March 27, 2023

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, DC.

Key Points: 
  • “We are very pleased to be presenting these data from across the bexotegrast clinical development program, including data from our Phase 2a trial in patients with IPF,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • “These presentations provide further insight into bexotegrast’s mechanism of action and support the continued development of this novel drug candidate.”
    The following abstracts are posted on ATS 2023’s online itinerary planner.
  • Location: Area J, Hall C (Lower Level), Walter E. Washington Convention Center
    Pliant was also selected for featured oral presentations as part of the ATS 2023 Mini Symposiums program.
  • Location: Ballroom B (Level 3), Walter E. Washington Convention Center
    Location: Room 146 A-C (Street Level), Walter E. Washington Convention Center

Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

Retrieved on: 
Thursday, March 23, 2023

EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society (ATS) International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.

Key Points: 
  • EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society (ATS) International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.
  • The data to be presented by Mrs. Safaa Naiel, Ph.D. candidate, springs from the expanded research collaboration between Ceapro and McMaster researchers, Dr. Kjetil Ask, Dr. Todd Hoare and Dr. Martin Kolb, which is studying the anti-fibrotic properties of Ceapro’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and its potential as an inhalable immuno-therapeutic/-prophylactic in lung fibrotic diseases.
  • For more information about the conference, please visit the event website here .

Acuiti Labs is Platinum Sponsor for International Conference on BRIM by SAP and TAC Events

Retrieved on: 
Monday, September 12, 2022

LONDON, Sept. 12, 2022 /PRNewswire-PRWeb/ -- Companies that adopted subscription models have proven more resilient through the pandemic. In an increasingly digitally connected world, organizations across all industries are adopting the journey to propose personalized offerings and build stronger, longer-lasting relationships with clients.

Key Points: 
  • Acuiti Labs is proud to be sponsoring the first in-person International Conference on Billing and Revenue Innovation Management, presented by SAP and TAC Events, which is happening this year in Chicago, 26-27 October 2022.
  • Why should you attend the upcoming International Conference on BRIM?
  • Relax after the first day of the conference (October 26) with your colleagues and friends it's not to be missed!
  • As an SAP Silver Partner, and an SAP BRIM company, Acuiti Labs has been delivering business technology solutions & digital transformation deploying SAP BRIM (Billing) on S/4HANA and cloud-based applications such as Subscription Billing, CPQ & Entitlement Management.

Proactive news headlines including Paradigm Biopharmaceuticals, Andromeda Metals, Frontier Energy and Imugene Ltd

Retrieved on: 
Monday, August 8, 2022

Click here

Key Points: 
  • Click here
    Rumble Resources Ltd (ASX:RTR)s earn-in partner, AIC Mines Ltd, has updated the market on exploration at the Lamil gold-copper project in WAs Paterson Province.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

ATD Recognizes Exceptional Achievements in the Talent Development Industry

Retrieved on: 
Wednesday, May 18, 2022

ALEXANDRIA, Va., May 18, 2022 /PRNewswire-PRWeb/ -- During its 2022 International Conference & Exposition in Orlando, Florida, the Association for Talent Development (ATD) recognized organizations and individuals for their excellence and contributions across the talent development field.

Key Points: 
  • The Association for Talent Development honors organizations and individuals for their commitment to workplace talent development practices.
  • ALEXANDRIA, Va., May 18, 2022 /PRNewswire-PRWeb/ -- During its 2022 International Conference & Exposition in Orlando, Florida, the Association for Talent Development (ATD) recognized organizations and individuals for their excellence and contributions across the talent development field.
  • This award recognizes innovation that has had a measurable impact on an organization or audience, is moving the talent development industry forward, is sustainable, and is replicable within or outside the talent development field.
  • This award recognizes the work of talent development professionals and was developed for individuals whose primary role or job is within the talent development field.